ONCY Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Oncolytics Biotech Inc (ONCY) is not a strong buy at this moment for a beginner investor with a long-term strategy. While there is insider buying activity and improving financials, the lack of strong technical signals, absence of news catalysts, and limited growth in financial metrics suggest holding off for now. The current pre-market decline and neutral hedge fund sentiment further support a cautious approach.
The MACD is slightly positive but contracting, indicating weakening momentum. RSI is neutral at 51.139, and moving averages are converging, suggesting no clear trend. Key support is at 0.983, and resistance is at 1.159. Pre-market price is below the pivot level, showing bearish sentiment.
Insider buying has increased by 134.84% over the last month, indicating confidence from company insiders. Financial performance shows improvement in net income and EPS YoY.
is also declining by 0.71%. Hedge funds remain neutral, and there is no recent congress trading data.
In Q3 2025, revenue remained at 0 with no YoY growth. Net income improved by 50.90% YoY but remains negative at -$14.4M. EPS improved by 16.67% YoY to -0.14. Gross margin remains at 0.
No recent updates on analyst ratings or price target changes.
